Prognostic value of proliferation markers: Immunohistochemical Ki-67 expression and cytometric S-phase fraction of women with breast cancer in Libya

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 421-431

  Ermiah, Eramah ^a,b   Buhmeida, Abdelbaset ^c   Abdalla, Fathi ^d   Khaled, Ben Romdhane ^e   Salem, Nada ^c   Pyrhönen, Seppo ^a   Collan, Yrjö ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b National Cancer Institute   (Libyan Arab Jamahiriya)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d Misurata Cancer Institute   (Libyan Arab Jamahiriya)

^e SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

Ki 67 expression; Libyan female breast cancer; Prognosis; S phase fraction

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; MONOCLONAL ANTIBODY; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE S PHASE; CYTOMETRY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIBYAN ARAB JAMAHIRIYA; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 84881207711     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.4944     Document Type: Article

References (39)

1. Abussa A. Hospital cancer registry annual report 2006. Sabratha, Libya: African Oncology Institute. 2007: 18-20.
2. El Mistiri M, Verdecchia A, Rashid I, El Sahli N, El Mangush M, Federico M. Cancer incidence in eastern Libya: the first report from the Benghazi Cancer Registry, 2003. International journal of cancer Journal international du cancer. 2007; 120: 392-7. doi:10.1002/ijc.22273.
3. Abulkhair O, Saghir N, Sedky L, Saadedin A, Elzahwary H, Siddiqui N, et al. Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region. J Natl Compr Canc Netw. 2010; 8 Suppl 3: S8-S15.
4. Stapleton JM, Mullan PB, Dey S, Hablas A, Gaafar R, Seifeldin IA, et al. Patient-mediated factors predicting early- and late-stage presentation of breast cancer in Egypt. Psychooncology. 2011; 20: 532-7. doi:10.1002/pon.1767.
5. Boder J, Abdalla F, Elfageih M, Abusaa A, Alfagieh M, Buhmeida A, et al. Breast cancer patients in Libya: Comparison with European and central African patients. Oncology Letters. 2011; 2: 323-30.
6. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clinical immunology (Orlando, Fla). 2002; 102: 169-78. doi:10.1006/clim.2001.5163.
7. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11: 174-83. doi:10.1016/s1470-2045(09)70262-1.
8. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005; 23: 7212-20. doi:10.1200/jco.2005.07.501.
9. Collan YU, Eskelinen MJ, Nordling SA, Lipponen P, Pesonen E, Kumpusalo LM, et al. Prognostic studies in breast cancer. Multivariate combination of nodal status, proliferation index, tumor size, and DNA ploidy. Acta Oncol. 1994; 33: 873-8.
10. Friedrich K, Scheithauer J, Dimmer V, Meyer W, Theissig F, Haroske G, et al. DNA ploidy and chromosomal imbalances in invasive ductal breast cancer. A comparative study of DNA image cytometry and comparative genomic hybridization (CGH). Anal Cell Pathol. 2000; 20: 69-82.
11. Yildirim-Assaf S, Coumbos A, Hopfenmuller W, Foss HD, Stein H, Kuhn W. The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer. J Clin Pathol. 2007; 60: 649-55. doi:10.1136/jcp.2005.035550.
12. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991; 67: 421-8.
13. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP. The long-term prognostic significance of the thymidine labelling index in breast cancer. International journal of cancer Journal international du cancer. 1984; 33: 441-5.
14. Cooper LS, Gillett CE, Smith P, Fentiman IS, Barnes DM. Cell proliferation measured by MIB1 and timing of surgery for breast cancer. Br J Cancer. 1998; 77: 1502-7.
15. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991; 138: 867-73.
16. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, von Smitten K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer. 1993; 68: 579-83.
17. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002; 40: 2-11.
18. Goodson WH, 3rd, Moore DH, 2nd, Ljung BM, Chew K, Mayall B, Smith HS, et al. The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat. 2000; 59: 113-23.
19. Zhang S, Yuan Y, Wang X. [Prognosis prediction of S-phase fraction and p53, c-erbB-2, estrogen receptor, progesterone receptor in axillary node-negative breast cancer]. Zhonghua Wai Ke Za Zhi. 1997; 35: 475-7.
20. Michels JJ, Duigou F, Marnay J. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity. Breast Cancer Res Treat. 2000; 62: 117-26.
21. Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC, et al. MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer. 1998; 78: 460-5.
22. [Internet] AJCC. 5th Edition AJCC Cancer Staging Manual; Lippincott- Raven. 1999. http://www.cancerstaging.org/products/csmanual5ed. pdf.
23. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11: 155-68.
24. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. International journal of cancer Journal international du cancer. 1997; 74: 433-7.
25. Pinto AE, Andre S, Pereira T, Nobrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol. 2001; 54: 543-9.
26. Hedley DW, Friedlander ML, Taylor IW. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry. 1985; 6: 327-33.
27. Gaub J, Auer G, Zetterberg A. Quantitative cytochemical aspects of a combined feulgen-naphthol yellow S staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells. Exp Cell Res. 1975; 92: 323-32.
28. Bohnhoff GL. Setting up proper illumination on your microscope. Am J Med Technol. 1979; 45: 650-1.
29. Haroske G, Giroud F, Reith A, Bocking A. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations and recommendations for preparation, measurement and interpretation. European Society for Analytical Cellular Pathology. Anal Cell Pathol. 1998; 17: 189-200.
30. Visscher DW, Zarbo RJ, Greenawald KA, Crissman JD. Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. Pathol Annu. 1990; 25 (Pt 1): 171-210.
31. Leivonen M, Krogerus L, Nordling S. DNA analysis in advanced breast cancer. Cancer Detect Prev. 1994; 18: 87-96.
32. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, et al. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat. 1993; 28: 9-20.
33. Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010; 17: 269-75. doi:10.1007/s12282-009-0161-5.
34. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996; 2: 585-92.
35. Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. International journal of cancer Journal international du cancer. 1994; 57: 822-9.
36. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology. 2006; 48: 674-82. doi:10.1111/j.1365-2559.2006.02402.x.
37. Huovinen R, Warri A, Collan Y. Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene. International journal of cancer Journal international du cancer. 1993; 55: 685-91.
38. Lipponen P, Eskelinen M, Papinaho S, Klemi PJ, Aaltomaa S, Kosma VM, et al. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer. Anticancer research. 1992; 12: 677-82.
39. Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, et al. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer. 1997; 75: 1525-33